bioMérieux S.A. (BMXXY)

OTCMKTS · Delayed Price · Currency is USD
14.62
+0.79 (5.71%)
At close: Aug 5, 2025
5.71%
Market Cap17.62B
Revenue (ttm)4.12B
Net Income (ttm)447.46M
Shares Outn/a
EPS (ttm)3.77
PE Ratio39.38
Forward PE28.05
Dividend0.06 (0.39%)
Ex-Dividend DateJun 10, 2025
Volume100
Average Volume8,920
Open14.62
Previous Close13.83
Day's Range14.62 - 14.62
52-Week Range12.95 - 14.62
Beta0.45
RSIn/a
Earnings DateSep 4, 2025

About bioMérieux

bioMérieux S.A. develops and markets in vitro diagnostic solutions for infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It offers CHROMID RANGE, a chromogen culture media; RAPIDEC CARBA NP biochemical test for the detection of carbapenemase producing bacteria; air, surface, and water monitoring systems; BACT/ALERT VIRTUO or 3D, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction system; BIOFIRE SPOTFIRE Lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VI... [Read more]

Sector Healthcare
Founded 1963
Employees 14,754
Stock Exchange OTCMKTS
Ticker Symbol BMXXY
Full Company Profile

Financial Performance

In 2024, bioMérieux's revenue was 3.98 billion, an increase of 8.31% compared to the previous year's 3.67 billion. Earnings were 432.20 million, an increase of 20.86%.

Financial numbers in EUR Financial Statements

News

There is no news available yet.